AgingResearch.NewsJoin free

P-tau217 blood biomarker testing

Intervention

1 paper1 finding

  • In silico1

Outcomes

1

Quality-adjusted life-years

upin silico1

1 study

  1. P-tau217 blood biomarker testing increases quality-adjusted life-years in silico (891 incremental QALYs).

    “Results suggest that Strategy 1(blood biomarker testing alone) dominates Strategy 2, producing 891 incremental QALYs at the additional cost of $49.2million”

    In silicopreclinical AD screening simulation35 yearsn = 1,000

    COST EFFECTIVENESS ANALYSIS OF IMPLEMENTING A SCREENING PROGRAM FOR EARLY-STAGE ALZHEIMER’S DISEASE DETECTION

    GSA 2024 abstract31 Dec 2024

Latest

Related